Annual report [Section 13 and 15(d), not S-K Item 405]

Acquisitions, Licensing and Other Arrangements - Takeda (Details)

v3.25.1
Acquisitions, Licensing and Other Arrangements - Takeda (Details) - USD ($)
$ in Thousands
 1 Months Ended 12 Months Ended 218 Months Ended
Nov. 01, 2006
Feb. 28, 2009
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2024
Acquisitions, Licensing and Other Arrangements          
Revenue from contracts with customers     $ 6,650 $ 2,650  
Takeda Pharmaceutical Company Limited | Collaboration Agreement          
Acquisitions, Licensing and Other Arrangements          
Revenue from contracts with customers     100 100 $ 3,000
Maximum additional milestone payments entitled to receive     16,000   16,000
Contract assets     0 0 0
Contract liabilities     0 0 0
Capitalized contract costs     $ 0 $ 0 $ 0
Takeda Pharmaceutical Company Limited | Collaboration Agreement | TAK-079          
Acquisitions, Licensing and Other Arrangements          
Maximum milestone payments entitled to receive $ 19,000        
Minimum period eligible to receive royalties 13 years 6 months        
Royalty payment period from the first commercial sale of each royalty-bearing discovery product 12 years        
Takeda Pharmaceutical Company Limited | Collaboration Agreement | Other antibodies          
Acquisitions, Licensing and Other Arrangements          
Maximum eligible milestone payments receivable per discovery product candidate   $ 3,300      
Minimum period eligible to receive royalties   10 years